Is It Possible to Determine Breast Cancer Risk with a Blood Test?

According to the results of a study conducted by British scientists and published last week in the journal Genome Medicine, it may perhaps be possible to predict a woman’s risk of developing breast cancer with a simple blood test..
The researchers first identified an epigenetic marker. This marker was detected in women who had an inherited genetic mutation that makes them more susceptible to breast cancer.
This mutation occurs in the BRCA1 gene and is thought to be responsible for at least % 10 of breast cancers. The underlying causes of the remaining % 90 breast cancers have not been fully identified. Nevertheless, a growing number of studies have begun to suggest that genetic mutations are not the only contributors to the development of breast cancer.
These days, scientists are investigating how our genes regulate and express themselves (epigenetics). In other words, this research focuses on an epigenetic mechanism known as “DNA methylation,” which has been the subject of numerous studies.
The researchers analyzed blood samples collected in two large studies previously conducted in the United Kingdom. The blood samples were taken years before cancer developed in the participating women.
As a result of comparing DNA methylation markers in the women’s blood, it was found that women who developed both hereditary and non-hereditary breast cancer shared the same markers.
An epigenetic marker identified in the mutated BRCA1 gene is associated with an increased risk of cancer and lower survival rates. Surprisingly, this research team also found the same marker in women who did not carry the BRCA1 mutation, suggesting that the risk of breast cancer could be predicted years before diagnosis.
According to the research team, epigenetic markers may be responsible for genes being silenced in immune cells, and as a result of the silencing of these genes, immune cells may provide less protection against the development of breast cancer.
However, further studies are needed to determine whether this epigenetic marker can serve as an indicator of breast cancer risk and the course of the disease.
It is exciting to think that, in the future, blood-based epigenetic tests providing rapid results could be used to determine breast cancer risk in women without the need to investigate potentially dangerous genetic mutations.
Sources
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
Genome Med. 2014 Jun 27;6(6):47. doi: 10.1186/gm567
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.